| Project/Area Number |
09671450
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Teikyo University |
|---|
Principal Investigator |
MATSUNO Akira Teikyo University, School of Medicine, Associate Professor, 医学部, 助教授 (00242058)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAMURA Akira Teikyo University, School of Medicine, Professor, 医学部, 教授 (80111532)
TANAKA Hideki Teikyo University, School of Medicine, Staff Assistant, 医学部, 助手 (50276713)
NAGASHIMA Tadashi Teikyo University, School of Medicine, Professor, 医学部, 教授 (70217991)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 1998: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1997: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | antisense oligonucleotide / glioma / gene therapy / Microtubule-associated protein / growth suppression |
|---|
| Research Abstract |
Microtubule-associated protein (MAP) lA, one of the well-known MAPs that are essential for the various bioactivities, is known to be expressed in cultured glioma cells such as rat C6 glioma cells. The antisense oligodeoxynucleotide for MAP lA is demonstrated, by colony forming assay, to have significantly suppressed the in vitro proliferation of rat 6 glioma cells. The effect of antisense oligodeoxynucleotide on the expression of MAP lA has been demonstrated by immunohistochemical staining. This report will be the first one describing the efficiency of antisense oligodeoxynucleotide for MAP lA on the growth suppression of rat C6 glioma cells. The effect of antisense oligodeoxynucleotide for MAP 1A on the cell cycle of rat C6 glioma cells has also been shown by the flow cytometrical analysis. The suppression of MAP IA resulted in GL arrest of C6 glioma cells, and this result strongly suggests the important role of MAP IA in the cell cycle. The suppression of MAP lA using antisense oligodeoxynudeotide strategy can be established as a novel antitumor therapy for gliomas.
|
